Skip to Content


In the US, Histrelin (histrelin systemic) is a member of the following drug classes: gonadotropin releasing hormones, hormones/antineoplastics and is used to treat Precocious Puberty and Prostate Cancer.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Categories

Antineoplastic agent

Gonadotropin releasing hormone (GnRH) agonist

Chemical Name

5-Oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-N²-benzyl-D-histidyl-L-leucyl-L-arginyl-N-etyl-L-prolinamide (WHO)

Foreign Names

  • Histrelinum (Latin)
  • Histrelin (German)
  • Histréline (French)
  • Histrelina (Spanish)

Generic Names

  • Histrelin (OS: USAN)
  • ORF 17070 (IS: Ortho)
  • RWJ 17070 (IS)

Brand Names

  • Vantas
    Orion, Lithuania; Orion, Latvia; Orion, Slovenia; Tuteur, Argentina
  • Supprelin LA
    Endo, United States
  • Vantas
    Endo, United States; Orion, Czech Republic; Orion, Spain; Orion, Ireland; Orion, Portugal; Orion Pharma, Germany
  • Vantasse
    Orion, Netherlands


ISInofficial Synonym
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.